dc.contributor.author | Hattrem, Magnus Nergård | |
dc.contributor.author | Dille, Morten Johnsen | |
dc.contributor.author | Seternes, Tore | |
dc.contributor.author | Ege, Thorfinn | |
dc.contributor.author | Draget, Kurt Ingar | |
dc.date.accessioned | 2018-07-05T12:45:28Z | |
dc.date.available | 2018-07-05T12:45:28Z | |
dc.date.issued | 2017-04-25 | |
dc.description.abstract | The first aim of the present study was to evaluate the bioavailability of ibuprofen dispersed in a novel soft chewable
formulation compared with a traditional ibuprofen tablet; its second was to map the quality of taste masking and patient
product satisfaction. In a phase 1, single-center, open-label, randomized, crossover study, healthy subjects received a softchew
formulation or a hard tablet (reference),both containing 100 mg ibuprofen.Serial blood samples were collected over
24 hours to assess ibuprofen bioavailability. Taste and satisfaction after chewing the novel formulation 3 or 8 times were
evaluated with a questionnaire. The soft-chew formulation showed comparable bioavailability to the reference tablet.
The highest peak plasma concentration was observed after 3 chews, and the relative bioavailability was approximately
8% higher compared to 8 chews. The overall flavor was well appreciated, and chewing 3 times was significantly preferred
(<i>P</i> = .043) over chewing 8 times. Soft chewable drug formulations may improve compliance and potentially benefit several
subpopulations who experience dysphagia. | en_US |
dc.description.sponsorship | Vitux Pharma AS | en_US |
dc.description | Source at: <a href=http://doi.org/10.1002/cpdd.357> http://doi.org/10.1002/cpdd.357</a> | en_US |
dc.identifier.citation | Hattrem, M. N., Dille, M. J., Seternes, T., Ege, T. & Draget, K. I. (2017). The Relative Bioavailability of Ibuprofen After Administration With a Novel Soft Chewable Drug Formulation. Clinical pharmacology in drug development, 7(2), 168-176. http://doi.org/10.1002/cpdd.357 | en_US |
dc.identifier.cristinID | FRIDAID 1475531 | |
dc.identifier.doi | 10.1002/cpdd.357 | |
dc.identifier.issn | 2160-763X | |
dc.identifier.issn | 2160-7648 | |
dc.identifier.uri | https://hdl.handle.net/10037/13162 | |
dc.language.iso | eng | en_US |
dc.publisher | American College of Clinical Pharmacology | en_US |
dc.relation.journal | Clinical pharmacology in drug development | |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medisinske Fag: 700::Helsefag: 800::Ernæring: 811 | en_US |
dc.subject | VDP::Medical disciplines: 700::Health sciences: 800::Nutrition: 811 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Helsefag: 800 | en_US |
dc.subject | VDP::Medical disciplines: 700::Health sciences: 800 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728 | en_US |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728 | en_US |
dc.title | The Relative Bioavailability of Ibuprofen After Administration With a Novel Soft Chewable Drug Formulation | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |